5 Key Takeaways

• 1

  T-knife Therapeutics has launched a Phase 1 trial of TK-6302, a CRISPR-engineered T cell therapy targeting PRAME-expressing solid tumors.

• 2

  The ATLAS trial will evaluate TK-6302 in patients with advanced PRAME-positive cancers and is set to begin later this year.

• 3

  TK-6302 incorporates a high-affinity receptor for PRAME and genetic modifications to enhance T cell persistence and activity in tumors.

• 4

  Preclinical studies indicated that TK-6302 effectively eliminated tumor growth and demonstrated superior anti-tumor activity compared to control cells.

• 5

  If successful, TK-6302 could broaden the application of engineered T cell therapies to solid tumors, improving outcomes in challenging cases.